Skip to main content
Caplight Logo









Antikor Biopharma

Antikor Biopharma

Private
StevenageHealthcare & Life Scienceshttps://www.antikor.co.uk/

Last Round

Grant

Nov 1, 2024

Total Funding Raised

$1.51M

Company Overview

Antikor Biopharma is a biotechnology company that specializes in the discovery and development of small-format Antibody Fragment Drug Conjugates (FDCs) for the treatment of solid tumors.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Non-AI

Keywords

antibody-fragment drug conjugatesFDConcology therapeuticsantibody-drug conjugatesADCbioconjugationsolid tumor treatmenttargeted cancer therapybiotech licensingpreclinical drug developmentcytotoxic payloadsantibody fragmentsnext-gen ADCsdrug discovery

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Antikor Biopharma Comparables

Compare Antikor Biopharma with similar companies based on industry and business-model similarity.

Antikor Biopharma comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Crescendo Biologics Ltd.
75%
Avacta Group
70%
Bicycle Therapeutics
69%

Antikor Biopharma Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantNov 1, 2024
GrantApr 1, 2022
VC RoundJul 31, 2019

Key People

Founding team and executive leadership

Mahendra Deonarain

Chief Executive Officer, Chief Science and Operating Officer

Executive Team

Antikor Biopharma Investors

Notable investors and investment history

Antikor Biopharma investors
InvestorRounds
Essex Bio-TechnologyVC Round
Innovate UKGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 20, 2026

    Monthly visitors increased 31% MoM.

  • Apr 4, 2026

    Monthly visitors increased 121% MoM.

Antikor Biopharma Filings

Explore SEC and related filing metadata, where available.

Antikor Biopharma filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Antikor Biopharma's valuation, stock price, and market status.

Is Antikor Biopharma a public or private company?

Antikor Biopharma is a private company.

What is the current stock price of Antikor Biopharma?

Antikor Biopharma is a private company with no public stock price. No recent secondary market data is available.

How much is Antikor Biopharma worth (valuation)?

Valuation information for Antikor Biopharma is not publicly available.

Can I buy Antikor Biopharma stock?

Antikor Biopharma shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Antikor Biopharma's last funding round?

Antikor Biopharma's most recent funding round was Grant on November 1, 2024.

Who are the main investors in Antikor Biopharma?

Key investors in Antikor Biopharma include Essex Bio-Technology.

Will Antikor Biopharma IPO soon?

No public IPO plans have been announced for Antikor Biopharma.

How can I track Antikor Biopharma secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Antikor Biopharma's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersStevenage
Employee Range13
Year Founded2014
Last FundingNov 1, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?